Cargando…

Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial

IMPORTANCE: There is limited evidence to guide stage I to II small cell lung cancer (SCLC) treatment. OBJECTIVE: To examine the characteristics and outcomes among patients with stage I to II SCLC treated with modern chemoradiotherapy. DESIGN, SETTING, AND PARTICIPANTS: In this post hoc secondary ana...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salem, Ahmed, Mistry, Hitesh, Hatton, Matthew, Locke, Imogen, Monnet, Isabelle, Blackhall, Fiona, Faivre-Finn, Corinne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2018
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439849/ https://www.ncbi.nlm.nih.gov/pubmed/30520977 http://dx.doi.org/10.1001/jamaoncol.2018.5335

Ejemplares similares

Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2021)

Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study
por: Haslett, Kate, et al.
Publicado: (2021)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status
por: Faivre-Finn, Corinne, et al.
Publicado: (2016)

Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations
por: Muñoz-Guglielmetti, Diego, et al.
Publicado: (2021)

Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction
por: Zhao, Qun, et al.
Publicado: (2015)

Reliability and prognostic value of radiomic features are highly dependent on choice of feature extraction platform
por: Fornacon-Wood, Isabella, et al.
Publicado: (2020)

Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized Clinical Trial
por: Tang, Qing-Nan, et al.
Publicado: (2021)

(18)F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial
por: Manoharan, Prakash, et al.
Publicado: (2019)

Postoperative Adjuvant Chemoradiotherapy on the Survival of Stage III Gastric Cancer
por: Li, Chao, et al.
Publicado: (2022)

Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial)
por: Taylor, Sally, et al.
Publicado: (2021)

Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study
por: Haslett, Kate, et al.
Publicado: (2016)

Utility of Restaging MRI Following Neoadjuvant Chemoradiotherapy for Stage II-III Rectal Adenocarcinoma
por: Aryan, Mahmoud, et al.
Publicado: (2021)

Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging
por: Salem, Ahmed, et al.
Publicado: (2018)

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
por: Faivre-Finn, Corinne, et al.
Publicado: (2017)

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
por: Sher, David J.
Publicado: (2017)

Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer
por: Ma, Gui-Fen, et al.
Publicado: (2019)

Retracted: Postoperative Adjuvant Chemoradiotherapy on the Survival of Stage III Gastric Cancer
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
por: Spigel, David R., et al.
Publicado: (2022)

Radiotherapy tumor volume for limited-stage small cell lung cancer: less is more
por: Levy, Antonin, et al.
Publicado: (2020)

Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis
por: Chang, Xiu-Jun, et al.
Publicado: (2016)

Concordance and Reproducibility of Melanoma Staging According to the 7th vs 8th Edition of the AJCC Cancer Staging Manual
por: Elmore, Joann G., et al.
Publicado: (2018)

Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for stage II–III resectable rectal cancer: a meta-analysis of randomized controlled trials
por: Song, Jin Ho, et al.
Publicado: (2017)

Adjuvant Pelvic Radiotherapy vs. Sequential Chemoradiotherapy for High-Risk Stage I-II Endometrial Carcinoma
por: El-Hadaad, Hend Ahmed, et al.
Publicado: (2012)

Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
por: Pichert, Matthew D., et al.
Publicado: (2022)

Oncologic Outcomes of Postoperative Chemoradiotherapy Versus Chemotherapy Alone in Stage II and III Upper Rectal Cancer
por: Yoon, Ji Eun, et al.
Publicado: (2019)

Improving survival of stage II‐III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy
por: Li, Yang, et al.
Publicado: (2020)

Association between radiotherapy protocol variations and outcome in the CONVERT trial
por: Mir, Romaana, et al.
Publicado: (2022)

Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)
por: Martel-Lafay, Isabelle, et al.
Publicado: (2021)

Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer
por: Kang, Ki Mun, et al.
Publicado: (2012)

Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer
por: Conibear, John
Publicado: (2020)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison
por: Soo, K-C, et al.
Publicado: (2005)

Colorectal Cancer Stage at Diagnosis Before vs During the COVID-19 Pandemic in Italy
por: Rottoli, Matteo, et al.
Publicado: (2022)

Influence of stage at diagnosis on survival differences for rectal cancer in three European populations
por: Monnet, E, et al.
Publicado: (1999)

Chemoradiotherapy vs radiotherapy for nonoperative early stage esophageal cancer: A seer data analysis
por: Li, Jiaxin, et al.
Publicado: (2020)

Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604)
por: Tahara, Makoto, et al.
Publicado: (2015)

Preliminary treatment results of proton beam therapy with chemoradiotherapy for stage I–III esophageal cancer
por: Takada, Akinori, et al.
Publicado: (2016)

IDO1 Activity Predicts Lung Toxicity in Patients with Unresectable Stage III NSCLC and Chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2023)

Postoperative chemoradiotherapy improves survival in patients with stage II–III esophageal squamous cell carcinoma: An analysis of clinical outcomes
por: Zou, Bingwen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pfl3gdcnjiav0mbrg2mfev9jhr